LAP3 and Cowden disease: These peptidases can either be used to produce gluten-free foods from gluten-containing raw materials (Rizzello et al. 2007), or they have been suggested as an oral therapy for CD, in which dietary gluten is hydrolyzed by coingested peptidases already in the mouth or stomach, thus preventing CD-specific immune reactions in the small intestine.